Activation of human eosinophils by platelet-activating factor (PAF) involves multiple signal transduction pathways. Among these, protein kinase C has been demonstrated both to mediate respiratory burst and to suppress an alternative pathway of activation of respiratory burst and arachidonic acid metabolism in eosinophils. We utilized inhibitors of protein tyrosine kinases (PTK) to elucidate the role of PTK in PAF-induced activation of eosinophils. Eosinophils were isolated from peripheral blood of atopic donors and stimulated with PAF in the absence or presence of broad-spectrum PTK inhibitors ± genistein or lavendustin A; an inhibitor of mitogen-activated protein (MAP) kinase activation ± tyrphostin AG126; or an inhibitor of Janus kinase 2 (Jak2) ± tyrphostin B42 (AG490). PAF induced superoxide anion (O 2 Å. ) generation, leukotriene C 4 (LTC 4 ) release, intracellular calcium ion mobilization and tyrosine phosphorylation of multiple eosinophil proteins in a concentration-dependent manner. All of these responses were concentrationdependently inhibited by genistein; lavendustin A also exhibited potent inhibition of PAF-induced LTC 4 release. AG126 had no effect on either O 2 Å. generation or LTC 4 release, while AG490 inhibited both responses, albeit less effectively than genistein. We conclude that PAF activates PTK in human eosinophils and that this signalling pathway is involved in eliciting respiratory burst and leukotriene production. The speci®c PTK(s) involved are unknown but may include Jak2.
INTRODUCTION
Eosinophils are immune effector cells that are particularly associated with immunoglobulin E (IgE) -dependent reactions, such as parasite killing and allergy. 1 They are the distinctive in®ltrating cells in human airways in asthma; eosinophilderived basic proteins, lipid mediators, reactive oxygen species (ROS) and cytokines have been implicated in allergic and asthmatic reactions. 2 The products of eosinophils stimulated with plateletactivating factor (PAF) have been demonstrated to induce contraction of airway smooth muscle 3, 4 and to damage respiratory epithelium in vitro. 5, 6 The former effect is mediated largely through the release of the cysteinyl leukotriene, LTC 4 . 3, 7 Activated eosinophils have also been shown to increase the responsiveness of bronchial smooth muscle to other contractile agents, 8 an action that can be mimicked in vivo by inhaled LTC 4 . 9 The toxic actions of activated eosinophils on respiratory epithelium appear to be mediated largely through a combination of ROS and granule proteins, particularly eosinophil peroxidase. 5, 10 Thus, both eicosanoid lipid mediator production and other aspects of eosinophil activation, including ROS generation, are important in the eosinophilic in¯ammation occurring in asthmatic airways.
The cell signalling pathways through which in¯ammatory mediators activate eosinophils have only recently begun to be elucidated. 11 We have recently identi®ed the role of protein kinase C (PKC) in the activation of eosinophil respiratory burst by PAF, measured as production of the ROS, superoxide anion radical (O 2 Å. ), but also found PKC activation to be responsible for damping of alternative pathways of activation for both respiratory burst and eicosanoid production. 12 The aim of the present study was to determine the role of an alternative set of signal transduction enzymes ± the protein tyrosine kinases (PTK) ± in these responses in eosinophils. The actions of PTK inhibitors were assessed on O 2 Å. generation and LTC 4 release, as well as on PAF-induced intracellular calcium concentration ([Ca 2+ ] i ) elevations and protein tyrosine phosphorylations, to determine the involvement of PTK both in early cell signalling events and in the release of active molecules from the cells.
MATERIALS AND METHODS

Cells
Eosinophils were isolated from acid citrate phosphate-anticoagulated blood of atopic, non-asthmatic donors by negative immunomagnetic selection using anti-CD16-coated microbeads, as described previously. 12 Cell preparations contained >90% eosinophils [95 . 5t0 . 50% (mean tSEM), n=37 from 20 donors; contaminants mostly mononuclear cells] which were >97% viable at the time of experimentation. Eosinophils were suspended in sterile-®ltered HEPES-bovine serum albumin (BSA) buffer, as described previously. 12 Cell suspensions were stored on ice for up to 20 min before experimentation. All experiments were performed in HEPES-BSA buffer.
Respiratory burst measurements
Superoxide anion (O 2 Å. ) generation was measured as the superoxide dismutase (SOD)-inhibitable reduction of ferricytochrome c, as described previously. 12 Results are expressed as nanomoles of cytochrome c reduced per 10 6 cells in 15 min.
Leukotriene production
Cysteinyl leukotriene release was measured as described previously. 12 As cell suspensions were almost exclusively eosinophils, all cysteinyl leukotriene measured was assumed to be LTC 4 . 7 Results are expressed as femtomoles of LTC 4 released per 10 6 cells in 5 min.
Measurement of intracellular Ca
2+
Intracellular Ca 2+ concentration ([Ca 2+ ] i ) was measured in Fura-2-loaded eosinophils, as described previously. 12 Measurement of protein phosphorylation Phosphorylation of tyrosine residues on eosinophil proteins was assessed by Western blotting. Eosinophils (10 6 ) were incubated for 10 min at 37u in the absence or presence of genistein prior to the addition of 1 mM PAF or an equal volume of HEPES-BSA buffer. Mixtures were incubated for 1±20 min, after which cells were precipitated by centrifugation. Supernatants were discarded; cell pellets were disrupted in 100 ml denaturing lysis buffer (composition: Tris±HCl, 20 mM; NaCl, 40 mM; Nonidet P-40, 1% v/v; deoxycholic acid, 0 . 5% w/v; ethylenediaminetetraacetic acid, 5 mM; leupeptin, 10 mg/ml; aprotinin, 5 mg/ml; phenylmethylsulphonyl¯uoride, 2 mM; NaF, 50 mM; sodium pyrophosphate, 30 mM; sodium orthovanadate, 2 mM; pH 7 . 4) on ice for 10 min. Lysates were centrifuged at 1000 g for 5 min to precipitate unbroken nuclei and cell debris; supernatants were mixed 1 : 1 with 4% sodium dodecyl sulphate (SDS) sample buffer (composition: Tris±HCl, 250 mM; SDS, 9 . 2% w/v; glycerol, 40% v/v; 2-mercaptoethanol, 20% v/v; bromophenyl blue, 0 . 004% w/v; pH 6 . 8) and boiled for 5 min. Proteins in cell lysates (approx. 25 mg per sample) were separated by 7 . 5% polyacrylamide gel electrophoresis and blotted onto polyvinylidene di¯uoride membranes (400 mA for Å. generation was signi®cantly higher than baseline in all cases (P<0 . 05). *P<0 . 05, **P<0 . 01, compared to control cells preincubated without inhibitors.
1 hr). Tyrosine-phosphorylated protein bands were stained using anti-phosphotyrosine antibody 4G10 (1 mg/ml for 1 hr) and detected by enhanced chemiluminescence (ECL+, Amersham Corp., Arlington Heights, IL).
Statistical analysis
Data are expressed as arithmetic mean tSEM or geometric mean with 95% con®dence interval (CI) from the indicated numbers of experiments.
All statistical analyses were performed using INSTAT 1 (GRAPHPAD 2 Software, San Diego, CA). Groups were compared by repeated-measures ANOVA. Comparisons between untreated (control) cells and cells pretreated with inhibitors were performed using Dunnett's test for multiple comparisons; comparisons between points on concentration±response curves obtained in the absence and presence of inhibitors were made using Bonferroni-corrected Student's t-tests. Indices of [Ca 2+ ] i changes were compared using paired Student's t-tests. A probability <0 . 05 was de®ned as signi®cant.
Materials
Fura-2 acetoxymethyl ester (Fura-2/AM), lyophilized PAF, lavendustin A (RG14355), tyrphostin A10 (AG126) and tyrphostin B42 (AG490) were purchased from CalbiochemNovabiochem GmbH [Bad Soden (Taunus), Germany]. Genistein and lavendustin A methyl ester were supplied by Alexis GmbH (Gru È nberg, Germany). Anti-FccRIII (CD16)-coated microbeads and magnetic separation apparatus (MACS system) were purchased from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). Cysteinyl leukotriene enzyme immunoassay (EIA) kits were obtained from Cayman Chemical Co. (Ann Arbor, MI). The 4G10 anti-phosphotyrosine monoclonal antibody was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Acid citrate phosphate, cytochrome c (type VI, from horse heart) and SOD were supplied by Sigma Chemie (Deisenhofen, Germany). All other reagents were of analytical grade.
Genistein, tyrphostins, lavendustin A and Fura-2/AM were dissolved in dimethyl sulphoxide. Lyophilized PAF was dissolved at 1 mM in deionized water 15±30 min before use. All compounds were diluted to the desired concentration in HEPES-BSA buffer.
RESULTS
Effects of PTK inhibitors on PAF-induced O 2
Å. generation
by human eosinophils that was consistently signi®cantly higher than basal production (P<0 . 05 in all sets of experiments). Both basal and PAFinduced O 2 Å. generation were inhibited in a concentrationdependent manner by the non-selective PTK inhibitor, genistein, with a median inhibitory concentration (IC 50 ) in PAF-stimulated cells of 0 . 93 mM (geometric mean, 95% CI 0 . 18±4 . 8 mM; Fig. 1a) .
To determine which PTK(s) might participate in this response, two drugs with greater selectivity were studied. Tyrphostin AG126 had no signi®cant effect on either basal or PAF-induced O 2 Å. generation (Fig. 1b) . In contrast, tyrphostin B42 (AG490) caused signi®cant suppression of PAF-induced O 2 Å. generation at concentrations in the range 0 . 1±10 mM (Fig. 1c) .
Effects of PTK inhibitors on PAF-induced LTC 4 release
PAF induced a concentration-dependent release of LTC 4 from human eosinophils in the range 20 nMx20 mM that declined at higher concentrations (not shown). In the presence of 10 mM genistein, PAF-induced LTC 4 release was abolished (Fig. 2a) . A second broad-spectrum PTK inhibitor, lavendustin A (as the cell-permeant methyl ester), also abolished PAF-induced LTC 4 release at 10 mM and inhibited substantially at 1 mM (Fig. 2b) . Lavendustin A methyl ester could not be studied for effects on O 2 Å. production owing to its deep orange colour, which interfered profoundly with the cytochrome c reduction assay.
Similarly to O 2 Å. production, PAF-induced LTC 4 release was unaffected by AG126 (Fig. 2c) but was inhibited by approximately 50% by 10 mM AG490 (Fig. 2d) .
Effects of genistein on [Ca
The possibility of suppression of early cell signalling events by PTK inhibition was addressed by studying the effect of genistein on PAF-induced Ca 2+ mobilization. Pre-incubation of eosinophils with 10 mM genistein for 10 min caused a small, non-signi®cant reduction in baseline [Ca 2+ ] i and had no effect on peak PAF-induced [Ca 2+ ] i elevations (Fig. 3) . The return of [Ca 2+ ] i to baseline levels after peaking, however, was accelerated in the presence of genistein (Fig. 3) 
Effects of genistein on PAF-induced protein tyrosine phosphorylation
PAF (1 mM) caused a time-dependent phosphorylation of tyrosine residues on a number of eosinophil proteins (Fig. 4a) . There was notable, reversible tyrosine phosphorylation of proteins with apparent molecular masses of 30 000 and below, and of 63 000 and 109 000. Genistein caused a concentrationdependent inhibition of the PAF-induced phosphorylation of all of these proteins with similar potency (Fig. 4b,c) . Within the range of concentrations of genistein that were effective in suppressing eosinophil functions, the degree of inhibition of PAF-induced tyrosine phosphorylation was less than 50% (Fig. 4c) .
DISCUSSION
The objective of this study was to identify the role of PTK in mediating responses of human eosinophils to the in¯ammatory mediator, PAF. The broad-spectrum PTK inhibitor, genistein, was used to demonstrate PTK involvement in respiratory burst, LTC 4 production and Ca 2+ mobilization responses, while two more selective inhibitors ± AG126, which inhibits tyrosine phosphorylation of p42 MAPK , 13 and AG490, which inhibits the activity of Janus kinase 2 (Jak2) 14, 15 ± were studied to determine which PTKs might be involved in eosinophil activation.
PAF stimulated respiratory burst and LTC 4 release in eosinophils and also induced increases in cytoplasmic free calcium concentration [Ca 2+ ] i , which may be involved in the activation of one or both of these responses. 16, 17 PAF also induced rapid, transient phosphorylation of tyrosine residues on multiple eosinophil proteins, indicating the activation of one or more tyrosine kinase enzyme(s). Genistein suppressed both Table 1 . Å. generation and LTC 4 release in human eosinophils, demonstrating that tyrosine kinase activation is required for induction of both of these responses. A second broad-spectrum PTK inhibitor, lavendustin A, also potently inhibited PAFinduced LTC 4 release, con®rming the dependence of this response on PTK.
We have demonstrated previously that an augmentation of PAF-induced eicosanoid (thromboxane and LTC 4 ) production in eosinophils by PKC inhibitors is accompanied by an increase in both peak and post-peak [Ca 2+ ] i . 12 Since this indicates possible involvement of intracellular calcium mobilization in PAF-induced LTC 4 production, we investigated the effect of genistein, at a concentration that inhibits this response, on the [Ca 2+ ] i signal following PAF stimulation of eosinophils. While peak [Ca 2+ ] i was unaffected by 10 mM genistein, the post-peak return to baseline was accelerated signi®cantly, indicating that ] i`s pike' is apparently independent of PTK. The ®nding that a PKC inhibitor and a PTK inhibitor ± drugs that have opposite actions on PAFinduced LTC 4 release ± also have opposite effects on PAFinduced Ca 2+ mobilization supports the hypothesis that the generation of arachidonic acid metabolites in eosinophils is dependent upon [Ca 2+ ] i elevation. To identify which PTK(s) may be involved in transduction of PAF signals in eosinophils, we studied two more selective PTK inhibitors: tyrphostins AG126 and AG490. AG126 had no effect on either respiratory burst or LTC 4 release induced by PAF in eosinophils at a concentration close to that which abolishes lipopolysaccharide-induced tumour necrosis factor-a production in murine macrophages, suggesting that mitogenactivated protein kinase (MAPK) activation is unlikely to be required for transduction of PAF signals in human eosinophils. PAF has been demonstrated to induce transient activation of p42 MAPK (Erk2); 18 it might therefore seem surprising that AG126, which prevents Erk2 activation, 13 was without effect on PAF-induced eosinophil responses. In fact, suppression of Erk2 activation by an inhibitor of MAPK/Erk kinase (Mek) causes no inhibition of respiratory burst responses in PAFprimed eosinophils. 18 This ®nding indicates a similarity with leukotriene B 4 -stimulated guinea-pig eosinophils, in which p42/ p44 MAPK (Erk1/2) are activated but play no part in mediating either respiratory burst or arachidonic acid metabolism. 19 It seems likely that PAF activates Erk2 in human eosinophils but that Ca 2+ mobilization, respiratory burst and LTC 4 secretion are not dependent upon activation of this enzyme.
AG490, on the other hand, caused roughly 50% inhibition of both responses, indicating that both responses involve a PTK that is sensitive to inhibition by this tyrphostin. While AG490 has been demonstrated to exert inhibitory actions in leukaemic B lymphocytes through Jak2 inhibition, 14 it also inhibits receptor PTKs such as epidermal growth factor receptor kinase (EGFR-K) and EGFR-related kinases, 20 a property it shares with genistein 21 and lavendustin A 22 but not AG126. 23, 24 It should be noted, however, that AG490 is 30-fold more potent than genistein in inhibiting EGFR-K but was substantially less effective than genistein as an inhibitor of PAF-induced eosinophil activation. This suggests that the effect of AG490 is mediated by Jak inhibition while the additional effects of genistein and lavendustin A re¯ect inhibition of other PTKs that are insensitive to AG126 and AG490. Jak2 has been shown to be involved in interleukin-5 signalling in human eosinophils; 25 it is therefore a candidate for involvement in signalling in eosinophils activated with other G protein-coupled receptor stimuli.
Finally, the degree of inhibition by genistein of PAFinduced tyrosine phosphorylation observed in our experiments appears small in view of the drug's effectiveness in suppressing PAF-induced eosinophil functions. While the ability of genistein to inhibit tyrosine phosphorylation by only 50% may indicate the presence of some non-genistein-sensitive PTK, these activities remain to be identi®ed. However, the abolition of functional responses that we observed at concentrations of genistein producing only 50% inhibition of tyrosine phosphorylation is not unique: for example, AG490 produces near-total suppression of leukaemic lymphoblast proliferation at a concentration (5 mM) that causes only partial inhibition of protein tyrosine phosphorylation.
14 It would appear that a high level of tyrosine phosphorylation is required to effect some cell functions and that a 50% inhibition of PTK activity can have profound effects on PTK-dependent functions.
In conclusion, PAF activates one or more PTK in human eosinophils and this activation is involved in the maintenance of intracellular Ca 2+ elevations and in the generation of O 2 Å. and of LTC 4 by these cells. The speci®c PTK enzymes responsible for evoking these responses remain to be identi®ed but may include an AG490-sensitive Jak2. 
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